EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort

Kassem Bourgi iD, Susan Ofner, Beverly Musick, Kara Wools-Kaloustian, John M Humphrey, Lameck Diero, Constantin T Yiannoutsos, Samir K Gupta

Open Forum Infectious Diseases · 01.12.2023 · 10 (12)

DOI: 10.1093/ofid/ofad581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 12.12.2023. Verfasst von Kassem Bourgi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Gilead HIV Scholars Program, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Switching from non-nucleoside reverse transcriptase inhibitor (NNRTI)–based regimens to dolutegravir (DTG) has been associated with greater weight gain.

Methods

We conducted our analysis using a longitudinal cohort of people with HIV (PWH) in Western Kenya. We evaluated changes in the rate of weight gain among treatment-experienced, virally suppressed PWH who switched from NNRTI to tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD). We modeled the weights pre- and postswitch using a 2-phase model with linear trend preswitch and an inverted exponential function postswitch. We estimated an 18-month excess weight gain by comparing the projected weight with that expected using the preswitch rate.

Results

A total of 18 662 individuals were included in our analysis, with 55% switching from efavirenz (EFV) and 45% from nevirapine (NVP). Of the studied individuals, 51% were female, and the median age and body mass index (BMI) were 51 years and 22 kg/m2, respectively. For the overall population, the rate of weight gain increased from 0.47 kg/year preswitch to 0.77 kg/year, with higher increases for females (0.57 kg/year to 0.96 kg/year) than males (0.34 kg/year to 0.62 kg/year). The rate of weight gain for individuals switching from EFV-based regimens significantly increased from 0.57 kg/year preswitch to 1.11 kg/year postswitch but remained stable at 0.35 kg/year preswitch vs 0.32 kg/year postswitch for individuals switching from NVP-based regimens.

Conclusions

Switching from NNRTI-based regimens to TLD is associated with a modest increase in the rate of weight gain, with the preswitch NNRTI being the key determinant of the amount of weight gain experienced postswitch.

Schlagwörter

Stichwörter der Autor:innen

Sub-Saharan Africadolutegravirefavirenzswitching antiretroviral therapyweight gain

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • School of Medicine, Department of Medicine, College of Health Sciences, Moi University Eldoret, Eldoret, Kenya.
  • Department of Biostatistics and Health Data Science, Indiana University R.M. Fairbanks School of Public Health, Indianapolis, Indiana, USA.

ORCID-Profile: Kassem Bourgi

Förderung

  • NIAID NIH HHS
  • Gilead HIV Scholars Program
  • NIH
  • East Africa IeDEA Consortium

Zitieren

APA

Bourgi, K., Ofner, S., Musick, B., Wools-Kaloustian, K., Humphrey, J. M., Diero, L., Yiannoutsos, C. T., & Gupta, S. K. (2023). Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort. Open Forum Infectious Diseases, 10(12). https://doi.org/10.1093/ofid/ofad581

Vancouver

Bourgi K, Ofner S, Musick B, Wools-Kaloustian K, Humphrey JM, Diero L, et al. Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort. Open Forum Infectious Diseases. 2023;10(12). doi:10.1093/ofid/ofad581

BibTeX
@article{Bourgi2023,
  author = {Bourgi, Kassem and Ofner, Susan and Musick, Beverly and Wools-Kaloustian, Kara and Humphrey, John M and Diero, Lameck and Yiannoutsos, Constantin T and Gupta, Samir K},
  title = {Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {12},
  doi = {10.1093/ofid/ofad581}
}
Kostenlos starten →